Keyphrases
Early Onset
100%
Fluvoxamine
100%
COVID-19
100%
Inhaled Budesonide
100%
Platform Trials
100%
Hospitalization
42%
Credible Interval
42%
Placebo
28%
Twice Daily
28%
Severe Disease
28%
Vaccinated Population
28%
Emergency Setting
28%
Placebo Groups
28%
Disease Progression
14%
Randomized Placebo-controlled Trial
14%
Risk Factors
14%
High Risk
14%
Brazil
14%
Patient-reported Outcomes
14%
Treatment Effect
14%
Disease Prevention
14%
Adverse Drug Reaction
14%
SARS-CoV-2 Infection
14%
Clinical Site
14%
Emergency Department Visits
14%
Adverse Events
14%
Between-group
14%
Relative Risk
14%
Treatment Group
14%
Event Rate
14%
Intervention Group
14%
Relative Effect
14%
Clinical Progression
14%
Advanced Care
14%
Probability of Superiority
14%
Adaptive Platform Trial
14%
Healthcare Attendance
14%
Medicine and Dentistry
COVID-19
100%
Fluvoxamine
100%
Budesonide
100%
Oral
100%
Placebo
71%
Outpatient
28%
Diseases
28%
Infection
14%
Disease Exacerbation
14%
Health Care
14%
Emergency Department
14%
Adverse Event
14%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Treatment Effect
14%
Adverse Drug Reaction
14%
Treatment Group
14%
Patient-Reported Outcome
14%
Primary Outcome
14%
Nursing and Health Professions
Fluvoxamine
100%
Budesonide
100%
COVID-19
100%
Placebo
71%
Outpatient
28%
Randomization
28%
Diseases
28%
Patient-Reported Outcome
14%
Emergency Ward
14%
Severe Acute Respiratory Syndrome
14%
Infection
14%
Disease Exacerbation
14%
Adverse Event
14%
Adverse Drug Reaction
14%
Treatment Group
14%
Health Care
14%
Pharmacology, Toxicology and Pharmaceutical Science
Fluvoxamine
100%
Budesonide
100%
Placebo
83%
Diseases
33%
Adverse Drug Reaction
16%
Infection
16%
Disease Exacerbation
16%
Adverse Event
16%
SARS Coronavirus
16%
Treatment Group
16%